NCT06181656

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 80 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To learn how radiation treatment may affect your responses to vaccines against pneumonia.

Detailed description

Primary Objectives \- Determine the impact of Grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination. Secondary Objectives * Determine the impact of chemoradiation on serologic responses to pneumococcal vaccination. * Determine the impact of radiation modality on serologic responses to pneumococcal vaccination. * Determine the impact of radiation modality on systemic immunity. * Determine the incidence of pneumonia among patients treated with a pneumococcal vaccine. * Determine the impact of radiation modality on pathologic response. * Determine the impact of radiation modality on intratumoral immunity. * Determine the relationship between changes in systemic and intratumoral immunity and clinical outcomes (i.e., incidence of pneumonia and pathologic response) * Determine the impact of tumor histology on serologic responses to pneumococcal vaccination.

Conditions

• Pneumococcal Vaccine
• Esophageal Cancer
• Lymphopenia
• Chemoradiation

Interventions

Type	Name	Description
BIOLOGICAL	Pneumonia vaccine	Given by SC

Timeline

• Start date: 2024-02-05
• Primary completion: 2027-07-04
• Completion: 2027-07-04
• First posted: 2023-12-26
• Last updated: 2026-02-19

Locations

1 site across 1 country: United States